Preserved supervised synthesis

Liraglutide synthesis · version 1

This URL preserves the exact reviewed public wording and source set for synthesis version 1.

Supervised synthesis

What do selected human studies report about Liraglutide?

Manually reviewed August 19, 2026 · version 1

Browse all Human Evidence Reviews · Open preserved synthesis version 1 →

A bounded review of two sponsor-funded randomized trials: one 56-week weight-management trial and one cardiovascular-outcomes trial in type 2 diabetes.12

Bottom line from this bounded source set

The reviewed weight-management trial reported greater mean weight reduction than placebo, and the reviewed cardiovascular trial reported fewer primary cardiovascular events in a high-risk type 2 diabetes population. The findings remain specific to the studied populations and trial conditions.12

Reviewed study record

SCALE weight-management trial

Design

A double-blind, randomized, placebo-controlled trial assessed body-weight change over 56 weeks alongside lifestyle counseling.1

Population

The trial randomized 3,731 adults without type 2 diabetes who had obesity, or overweight with dyslipidemia or hypertension.1

Outcomes reported

Reported mean weight loss was 8.4 kilograms with liraglutide and 2.8 kilograms with placebo. At least 5% weight loss was reported for 63.2% and 27.1%, respectively, and gastrointestinal events were common.1

Limitations

The sponsor-funded trial combined treatment with lifestyle counseling, excluded type 2 diabetes, and used imputation for the reported mean weight-change analysis.1

Reviewed study record

LEADER cardiovascular-outcomes trial

Design

A double-blind, randomized, placebo-controlled cardiovascular-outcomes trial followed participants for a median of 3.8 years.2

Population

The trial randomized 9,340 adults with type 2 diabetes and high cardiovascular risk in addition to standard care.2

Outcomes reported

The primary composite cardiovascular outcome occurred in 13.0% of the liraglutide group and 14.9% of the placebo group, with a reported hazard ratio of 0.87. Gastrointestinal events were the most common events leading to discontinuation.2

Limitations

The sponsor-funded findings apply to a high-cardiovascular-risk type 2 diabetes population receiving standard care and do not establish the same effect in lower-risk populations.2

Reviewed source set

  1. PubMed · 26132939A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management ↗PubMed PMID 26132939 · EFetch XML reviewed 2026-08-19 · payload SHA-256 5c94f293c86af2a279cfa8ae529f06100cf2dce79b2009b0a6ba26fb9ca9bce6
    No registered Crossref update in the reviewed snapshotChecked August 19, 2026 for DOI 10.1056/nejmoa1411892. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
  2. PubMed · 27295427Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes ↗PubMed PMID 27295427 · EFetch XML reviewed 2026-08-19 · payload SHA-256 d86dca944a90d406ed7a98e6e46eb8d9774504c7746b167351df04f923325e26
    No registered Crossref update in the reviewed snapshotChecked August 19, 2026 for DOI 10.1056/nejmoa1603827. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗